Back to Search
Start Over
Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.
- Source :
-
Clinical & translational immunology [Clin Transl Immunology] 2021 Jan 19; Vol. 10 (1), pp. e1239. Date of Electronic Publication: 2021 Jan 19 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Objectives: Francisella tularensis , the causative agent of tularaemia, is an exceptionally infectious bacterium, potentially fatal for humans if left untreated and with the potential to be developed as a bioweapon. Both natural infection and live-attenuated vaccine strain (LVS) confer good protection against tularaemia. LVS vaccination is traditionally administered by scarification, and the formation of a cutaneous reaction or take at the vaccination site is recognised as a clinical correlate of protection. Although previous studies have suggested that high antibody titres following vaccination might serve as a useful surrogate marker, the immunological correlates of protection remain unknown.<br />Methods: We investigated the host T-cell-mediated immune (T-CMI) responses elicited following immunisation with LVS vaccine formulated by the DynPort Vaccine Company (DVC-LVS) or the United States Army Medical Research Institute of Infectious Diseases (USAMRIID-LVS). We compared T-CMI responses prompted by these vaccines and correlated them with take size.<br />Results: We found that both LVS vaccines elicited similar T-CMI responses. Interestingly, take size associated with the T cells' ability to proliferate, secrete IFN-γ and mobilise degranulation, suggesting that these responses play an essential role in tularaemia protection.<br />Conclusions: These results renew the appreciation for vaccination through the scarification as a prime route of inoculation to target pathogens driving specific T-CMI responses and provide further evidence that T-CMI plays a role in protection from tularaemia.<br />Competing Interests: The authors declare no conflict of interest.<br /> (© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.)
Details
- Language :
- English
- ISSN :
- 2050-0068
- Volume :
- 10
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Clinical & translational immunology
- Publication Type :
- Academic Journal
- Accession number :
- 33505681
- Full Text :
- https://doi.org/10.1002/cti2.1239